Credit Suisse assumed coverage of Viridian Therapeutics with an Outperform rating and $51 price target. The analyst made no changes to the firm’s prior rating, target price, or estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
- VRDN Earnings this Week: How Will it Perform?
- Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
- UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology